Cytarabine Injection — Class II drug recall D-1680-2012
Terminated recall by Hospira Inc., reported 2012-09-26, distributed nationwide. The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel
| Recall number | D-1680-2012 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Hospira Inc., Lake Forest, IL, United States |
| Recall initiated | 2012-06-27 |
| Classified | 2012-09-19 |
| Reported by FDA | 2012-09-26 |
| Terminated | 2016-12-15 |
| Distributed | Nationwide (US) |
| Countries outside the US | AU, BE, CA, DE, FR, KR, MY, NO, NZ, PH, PK, PT, SE, SG, TH, VN |
| Quantity | 210 vials |
| Reason classes | foreign material |
| NDC | 61703-0303, 61703-0303-46 |
| Lot numbers | Y131994AA, Y141994AA, Y151994AA, Y161994AA, Y171994AA, Y181994AA |
| Expiration dates | 2013-08-20, 2013-09-20, 2013-11-20 |
Product
Cytarabine Injection, 20 mg/mL, 50 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia; NDC 61703-303-46
Reason for recall
The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1680-2012. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.